Abstract:Feng Yao, 1, &ast Chenguang Wang, 2, &ast Jie Ding, 1 Qian Zhang, 1 Liang Zheng, 1 Qin Zhang, 1 Tianshu Yang, 2 Xunmin Zhang, 2 Yong Shan, 2 Sheng Hou, 2 Hao Wang, 2 Renpeng Zhou, 1 Wei Hu 1 1 Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 2 Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Hu; Renpeng Zhou, Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui, 230601, People's Republic of China, Tel/Fax + 86 0551 65997164, Email ; Purpose: Secukinumab, a monoclonal antibody targeting interleukin (IL)-17A, is approved for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. This study compared the pharmacokinetics (PK), safety, and immunogenicity of CMAB015, a candidate secukinumab biosimilar, with the reference product secukinumab (Cosentyx ® ) in healthy Chinese male subjects. Patients and methods: This double-blind, parallel-group study randomized healthy Chinese male subjects (N=130) to receive either a single dose of 150 mg CMAB015 or secukinumab subcutaneously. Primary study endpoints were PK parameters such as the maximum concentration (C max ) and area under the curve from zero to infinity (AUC 0-inf ), while safety and immunogenicity were secondary endpoints. Results: The 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of C max and AUC 0-inf for CMAB015 to secukinumab were all within the bioequivalence limits (80.00– 125.00%). Other PK parameters were comparable between the groups. The safety profile of CMAB015 was similar to that of secukinumab, with no serious adverse events related to treatment. The incidence of TEAEs was slightly higher in the CMAB015 group, but these events were mild to moderate in severity and did not lead to any withdrawals from the study. Immunogenicity analysis revealed low rates of anti-drug antibody (ADA) positivity, with similar rates between CMAB015 and secukinumab. Conclusion: This study demonstrated equivalent PK, comparable safety, and immunogenicity of CMAB015 to secukinumab in healthy Chinese male subjects. These findings support further clinical evaluation of CMAB015 as a secukinumab biosimilar. Trial Registration: The trial was registered on Clinicaltrials.gov (Identifier No. NCT05734482) and Chinadrugtrials.org.cn (Identifier No. CTR20230105). Keywords: CMAB015, secukinumab, biosimilar, pharmacokinetics, safety, immunogenicity Interleukin-17A (IL-17A) is a pro-inflammatory cytokine belonging to the IL-17 family, known for its pivotal role in orchestrating inflammatory and immune responses. 1,2 Developed by Novartis, secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes IL-17A, thereby interrupting the inflammatory cascade driven by this cytokine. 3 The efficacy and safety of secukinumab have been well established in clinical trials, leading to its approval for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. 4–8 In particular, Phase III clinical trials have demonstrated the effectiveness of secukinumab in Chinese patients with moderate to severe plaque psoriasis, highlighting its potential as a valuable treatment option in this population. 9 Since its initial approval in Japan in December 2014, secukinumab has received regulatory approval in numerous countries, including the United States and the European Union, underscoring its global significance in the management of IL-17A-driven diseases. 10 The emergence of biosimilars offers a promising avenue for expanding access to effective biologic therapies while addressing cost considerations. A biosimilar is a biological product that is highly similar to an approved originator or reference product, with no clinically meaningful differences in safety, purity, or potency. 11 Biosimilars have the potential to increase treatment options for patients and healthcare providers, offering a more affordable alternative to costly biologic therapies. 12 The development and approval of biosimilars follow a well-regulated process in many countries. The European Medi -Abstract Truncated-

Characterization and Pre-Clinical Assessment of a Proposed Biosimilar to Its Originator Omalizumab

Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessment

Isolation and Characterization of Charge Variants of Infliximab Biosimilar HS626

An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases.

Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab

Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).

Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method

P134 Characterization for the similarity assessment between proposed biosimilar SB17 and ustekinumab reference product using state-of-the-art analytical method

Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers

Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial

Comparison of the Efficacy and Safety of the Adalimumab Biosimilar TQ-Z2301 and Adalimumab for the Treatment of Chinese Patients with Active Ankylosing Spondylitis: a Multi-Center, Randomized, Double-Blind, Phase III Clinical Trial

A Meta‐Analysis of the Safety and Immunogenicity of Pharmacokinetic Similarity Studies and Comparative Clinical Studies

Preclinical pharmacology and toxicology evaluation of an anti-CD52 monoclonal antibody produced by perfusion fermentation process

A Phase I Clinical Trial to Evaluate the Bioequivalence of an Adalimumab Biosimilar Adalimumab-WIBP and Humira®

Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product

A Randomized, Double‐Blind, Parallel Controlled, Single‐Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects

FRI0422 HS016, A PROPOSED ADALIMUMAB BIOSIMILAR, SHOWED EQUIVALENT PHARMACOKINETICS AND SIMILAR SAFETY, IMMUNOGENICITY AND TOLERABILITY TO CHINA-LICENSED ADALIMUMAB IN HEALTHY MALE SUBJECTS, ACCORDING TO A 2.3-MONTHS PHASE I STUDY

A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects

Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes

Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab